Page 69 - 2021_12-Haematologica-web

A centralized NGS diagnostic platform for AML
TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monoso- mal karyotype, and dismal outcome. Blood. 2012;119(9):2114-2121.
31. Gaidzik VI, Bullinger L, Schlenk RF, et al. RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. J Clin Oncol. 2011;29(10): 1364-1372.
32. Yoshimi A, Lin KT, Wiseman DH, et al. Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemo- genesis. Nature. 2019;574(7777):273-277.
33. Jain P, Kantarjian H, Patel K, et al. Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse. Leuk Lymphoma. 2014;55(6):1337-1344.
34.Schneider F, Hoster E, Unterhalt M, et al. NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in
patients with normal karyotype AML (NK- AML) or high-risk myelodysplastic syndrome (MDS). Blood. 2009;113(21):5250-5253.
Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia. Br J Haematol. 2016;175(2):226-
35. Ok CY, Loghavi S, Sui D, et al. Persistent
IDH1/2 mutations in remission can predict 236.
relapse in patients with acute myeloid leukemia. Haematologica. 2019;104(2):305- 311.
36. Megías-Vericat JE, Ballesta-López O, Barragán E, Montesinos P. IDH1-mutated relapsed or refractory AML: current chal- lenges and future prospects. Blood Lymphat Cancer Targets Ther. 2019;9:19-32.
37. Cocciardi S, Dolnik A, Kapp-Schwoerer S, et al. Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation. Nat Commun. 2019;10(1):2031.
38.Krönke J, Bullinger L, Teleanu V, et al. Clonal evolution in relapsed NPM1-mutat- ed acute myeloid leukemia. Blood. 2013;122(1):100-108.
39.Bhatnagar B, Eisfeld AK, Nicolet D, et al.
40. Hou HA, Kuo YY, Liu CY, et al. DNMT3A mutations in acute myeloid leukemia: sta- bility during disease evolution and clinical implications. Blood. 2012;119(2):559-568.
41.Gaidzik VI, Weber D, Paschka P, et al. DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia. Leukemia. 2018;32(1):30-37.
42. Larrosa-Garcia M, Baer MR. FLT3 Inhibitors in acute myeloid leukemia: cur- rent status & future directions. Mol Cancer Ther. 2017;16(6):991-1001.
43. Short NJ, Kantarjian H, Ravandi F, Daver N. Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia. Ther Adv Hematol. 2019;10:2040620719827310.
haematologica | 2021; 106(12)
3089